<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="567">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 16, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343729</url>
  </required_header>
  <id_info>
    <org_study_id>CAEE: 30615920.2.0000.0005</org_study_id>
    <nct_id>NCT04343729</nct_id>
  </id_info>
  <brief_title>Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19</brief_title>
  <acronym>MetCOVID</acronym>
  <official_title>Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a phase IIb, double-blind, randomized, placebo-controlled clinical trial to assess the
      efficacy and safety of injectable methylprednisolone sodium succinate (MPS) in patients with
      severe acute respiratory syndrome (SARS) in COVID-19 infection. A total of 420 individuals of
      both sexes, aged over 18 years old, with symptoms suggestive or confirmed diagnosis of severe
      acute respiratory syndrome (SARS), hospitalized at the Hospital and Pronto-Socorro Delphina
      Rinaldi Abdel Aziz (HPSDRAA), with clinical and radiological findings suggestive of SARS-CoV2
      infection, will be randomized at a 1:1 ration to receive either MPS (0.5mg/kg of weight,
      twice daily, for 5 days) or placebo (saline solution, twice daily, for 5 days).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate at day 28</measure>
    <time_frame>on day 28, after randomization</time_frame>
    <description>Mortality rate on day 28, after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with SARS</measure>
    <time_frame>after randomization, up to 7 days.</time_frame>
    <description>Number of patients with diagnosis of early onset of SARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate on days 7, 14 and 28</measure>
    <time_frame>after randomization, up to 28 days.</time_frame>
    <description>Proportion of patient that died on days 7, 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of orotracheal intubation</measure>
    <time_frame>after randomization, up to 7 days.</time_frame>
    <description>proportion of patients requiring orotracheal intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygenation index</measure>
    <time_frame>after randomization, up to 7 days.</time_frame>
    <description>Proportion of patients with oxygenation index (PaO2 / FiO2) &lt; 100 in 7 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution, twice daily, for 5 days. Injectable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone Sodium Succinate</intervention_name>
    <description>injectable solution at a dose of 0.5mg/kg</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>injectable saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected cases of COVID-19, due to clinical and radiological data, during the
             pandemic;

          2. Adult aged 18 years or older, at the time of inclusion (children under 18 will not be
             included due to the recognized lower lethality in previous published studies, and the
             difficulty of consent in the context of an emergency in public health);

          3. Present respiratory symptoms suggestive of SARS (cough OR dyspnoea) at the time of
             screening, or confirmed SARS diagnosis, taking into account the following: I.
             respiratory rate &gt; 24 breaths per minute or report of feeling short of breath OR satO2
             ≤ 94% in room air OR in use supplementary oxygen OR under invasive mechanical
             ventilation

        Exclusion Criteria:

          1. History of hypersensitivity to MPS;

          2. People living with HIV and AIDS;

          3. Chronic use of corticosteroids or immunosuppressive agents;

          4. Pregnancy or lactation;

          5. decompensated cirrhosis;

          6. Chronic renal failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcus Lacerda</last_name>
    <phone>+55 92 99114 7633</phone>
    <email>marcuslacerda.br@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Val</last_name>
    <phone>+55 92 99116 3107</phone>
    <email>ffaval@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69093-415</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Severe Acute Respiratory Syndrome (SARS) Pneumonia</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all patient data will be shared after study publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after study publication.</ipd_time_frame>
    <ipd_access_criteria>upon formal request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

